Observing the media’s enthusiastic reporting of a new breakthrough in treating prostate cancer, Stephen Pollard notes an oddly consistent omission:
[Despite] all the coverage, you would [still] have to guess where the research was carried out: the Weizmann Institute of Science, in Israel. . . .
I wish I could believe this is just an honest mistake—that, purely by chance, the Israeli origins of a medical breakthrough had been left out. But I’m afraid I don’t think that—and I don’t think you will, either. It happens too often and too regularly for it to be pure chance. It’s what I call the soft-boycott strategy.
The campaign for BDS is so obviously racist and anti-Semitic, singling out the Jewish homeland alone in the world for boycott, that some of those who would rather Israel didn’t exist choose an alternative approach—ignoring anything remotely positive about Israel and focusing only on bad news that fits their anti-Israel agenda.
And it is an unfortunate fact that many of those Israel-haters work in the media and have the ability to shape perceptions. So Israeli scientific breakthroughs . . . are reported as if they have simply happened by magic, with their Israeli origins ignored.